Free Trial
LON:AMYT

Amryt Pharma (AMYT) Share Price, News & Analysis

Amryt Pharma logo

About Amryt Pharma Stock (LON:AMYT)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
90,726 shs
Average Volume
469,552 shs
Market Capitalization
£457.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMYT Stock News Headlines

Amryt Pharma plc (AMYT)
Trump, Schiff and Dalio all point to the same warning sign
In 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.tc pixel
See More Headlines

AMYT Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include The Parkmead Group (PMG), Himax Technologies (HIMX), Falcon Oil & Gas (FO), Atalaya Mining (ATYM), AIB Group (AIBG), Amerisur Resources (AMER) and Agronomics (ANIC).

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
LON:AMYT
Previous Symbol
LON:FAST
CIK
N/A
Fax
N/A
Employees
290
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
66.05
Current Ratio
1.80
Quick Ratio
1.14

Sales & Book Value

Annual Sales
£210.24 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
3.68
Book Value
GBX 96.60 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
319,657,000
Free Float
N/A
Market Cap
£457.11 million
Optionable
Not Optionable
Beta
N/A
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (LON:AMYT) was last updated on 1/10/2022 by MarketBeat.com Staff.
From Our Partners